Abstract Extracellular adenosine concentrations in the brain increase dramatically during ischemia in concentrations that able to stimulate all (A 1 , A 2A , A 2B , and A 3 ) receptors. Adenosine exerts a clear neuroprotective effect through A 1 receptors during ischemia mainly by reducing precocious excitotoxic phenomena. Unfortunately, the use of selective A 1 agonists is hampered by undesirable peripheral effects. Evidence indicates that A 2A receptor antagonists administered early after ischemia provide protection centrally by reducing excitotoxicity. After ischemia, the primary damage due to the early massive increase of extracellular glutamate is followed by activation of resident immune cells, i.e., microglia, and production or activation of inflammation mediators and blood cell infiltration. Evidences are that agonists at A 2A, A 2B , and A 3 receptors mainly acting on blood and vascular endothelial cells provide protection by controlling neuroinflammation, endothelial leaking, and massive blood cell infiltration in the hours and days after brain ischemia. Since ischemia is a multifactorial pathology characterized by different events evolving in the time and protracted neuroinflammation is recognized as the predominant mechanism of secondary brain injury progression, adenosinergic drugs aimed at dampening damage in the hours/days after ischemia appear promising.
Introduction
Stroke is today evaluated as the second most common cause of death and a major cause of long-term disability worldwide. Ischemic stroke commonly accounts for approximately 80% of all stroke cases, and is caused from occlusion of a major cerebral artery by a thrombus or an embolism, which leads to loss of cerebral blood flow, a condition of hypoxia and glucose deprivation (oxygen/glucose deprivation: OGD) and subsequently tissue damage in the affected region. The only successful pharmacological treatment approved to date is tissue plasminogen activator (tPA) that aims to decrease ischemia-associated thrombosis risk. Yet, because of the narrow therapeutic time window involved, thrombolytic application is very restricted in clinical settings (Chen et al. 2014) . Aspirin, other antiplatelets, and anticoagulants are used as preventive therapy of stroke (Macrez et al. 2011) .
After stroke, brain injury results from a complex sequence of pathophysiological events consequent to hypoxia/ischemia that evolve over time (Dirnagl 2012) . A primary acute mechanism of excitotoxicity and periinfarct depolarizations is due to increased extracellular concentration of glutamate (see Fig. 14.1) . Excitotoxicity brings to activation of resident immune cells, i.e., microglia, and production or activation of inflammation mediators. In the hours and along days after ischemia, protracted neuroinflammation is recognized as the predominant mechanism of secondary brain injury progression (Tuttolomondo et al. 2009 ). Activated microglial cells proliferate, migrate, and, by production of inflammatory substances and chemokines, trigger an inflammatory response (Dirnagl et al. 1999) . Pro-inflammatory mediators and oxidative stress give rise to the endothelial expression of cellular adhesion molecules and to an altered permeability of the blood-brain barrier (BBB) that allows infiltration of leukocytes that on their turn exacerbate neuroinflammation and ischemic damage (Haskò et al. 2008; Iadecola and Anrather 2011) . A huge increase of extracellular adenosine concentrations matches the increase of glutamate in the first hours after ischemia (see Fig. 14 .1) as demonstrated under OGD conditions in vitro in the hippocampus (Dale et al. 2000; Frenguelli et al. 2007; Latini et al. 1998; Pedata et al. 1993) and in the in vivo models of brain ischemia (Dux et al. 1990; Hagberg et al. 1987; Matsumoto et al. 1992; Melani et al. 1999; Sciotti et al. 1992 ). In the first minutes after ischemia, the increase of extracellular adenosine concentration is due to the major part of extracellularly released ATP that is hydrolyzed by ectonucleotidases, and then, in the hours after ischemia, adenosine per se is mainly released from cells (Melani et al. 2012) . After in vivo ischemia, the extracellular concentrations of adenosine are high enough to stimulate all adenosine receptor subtypes (A 1 , A 2A , A 2B , and A 3 receptors) (Melani et al. 2012) . All receptor subtypes are expressed at significant levels in neurons and glial cells and in peripheral blood inflammatory cells (Burnstock and Boeynaems 2014) (see Fig. 14.2) . The wide distribution is consistent with the multifaceted neurochemical and molecular effects of adenosine and suggests that adenosine role in ischemia is the consequence of an interplay among different receptor activations in neuronal, glial, and inflammatory cells, which varies depending on the time-related development of the pathological condition. Numerous authors have proposed adenosine and adenosine receptors as important targets for therapeutic implementation in the treatment of stroke.
Role of Adenosine Receptors in Ischemia
The increase in extracellular adenosine early after ischemia has long been known as an endogenous neuroprotective response (Pedata et al. 2007 ). In fact, adenosine infusion into the ischemic striatum has been shown to significantly ameliorate neurological outcome and reduce infarct volume after transient focal cerebral ischemia (Kitagawa et al. 2002) . Adenosine protection has been attributed to stimulation of the A 1 receptor subtype; however important roles of the other three receptor subtypes have been outlined in the last 20 years. Cascade of pathogenetic mechanisms after ischemia. Primary mechanisms of excitotoxicity lead to acute cell death in the ischemic core. Depolarization spreads in the periinfart areas. Glutamate and extracellular adenosine concentrations increase in the first 4 h after ischemia (Melani et al. 1999 (Melani et al. , 2003 (Melani et al. , 2012 . The curves of increases of glutamate and adenosine evoked by ischemia and induced by middle cerebral artery occlusion (MCAo) were drawn on the basis of values obtained by striatal microdialysis (Melani et al. 1999 ). In the following several hours, activation of resident immune cells, i.e., microglia and production of a cascade of inflammation mediators, occurs. Cell death/neurogenetic responses progress along days/weeks after ischemia (figure modified from Dirnagl et al. 1999) . Putative therapeutic opportunities with purinergic drugs comprehend strategies aimed at reducing excitotoxicity in the first 4 h after ischemia with adenosine A 2A and A 2B receptor antagonists. In the hours and days after ischemia, agonists of adenosine A 2A , A 2B , and A 3 receptors peripherally located on vascular and blood cells may dampen vascular adhesion signals and neuroinflammation
Adenosine A 1 Receptors Are Protective
One of the prime adaptive mechanisms in response to hypoxia-ischemia is the cellular activation of adenosine A 1 receptors that inhibit excitatory synaptic transmission as demonstrated in vitro and in vivo (Latini and Pedata 2001) . Adenosine protective effects are greatly attributed to adenosine A 1 receptor activation that due to reduced Ca 2+ influx, lower presynaptic release of excitatory neurotransmitters (Corradetti et al. 1984; Dunwiddie 1984) and in particular glutamate which exerts an excitotoxic effect during ischemia mainly by overstimulation of NMDA Fig. 14.2 Schematic drawing of adenosine receptors on different cell types. All adenosine receptor subtypes are expressed both at the central level on presynaptic and postsynaptic neurons, on astrocytes, on microglia, and on oligodendrocytes and at the peripheral level on leukocytes and vasculature. After cerebral ischemia, leukocytes infiltrate into ischemic tissue due to increased permeability of BBB. During ischemia, extracellular adenosine levels increase mainly due to (i) extracellular ATP degradation by NTPDase and ecto-5′-nucleotidase enzymes; (ii) release per se from cells likely by the equilibrative nucleoside transporter (ENT) (Melani et al. 2012) ; and (iii) inhibition of adenosine uptake processes due to downregulation of concentrative nucleoside transporters (CNT) 2 and 3 and of ENT. ADO, adenosine; ADP, adenosine diphosphate; AMP, adenosine monophosphate; ATP, adenosine triphosphate; E5'-NT, ecto-5'-nucleotidase; NT, nucleoside transporter; NTDPase, ectonucleoside triphosphate diphosphohydrolases. The proportions of the various components of the nervous tissue have not been kept (Choi 1990 ) and AMPA receptors (Stockwell et al. 2016 ). In addition, by directly increasing the K + and Cl − ion conductances, adenosine stabilizes the neuronal membrane potentials, thus reducing neuronal excitability (Choi 1990) . Consequent reductions in cellular metabolism and energy consumption (Greene and Haas 1991) and moderate lowering of the body/brain temperature (Tupone et al. 2013; Muzzi et al. 2013 ) protect against ischemia. A continuous infusion of the adenosine A 1 receptor agonist (6)N-cyclohexyladenosine (CHA) that maintains the body temperature between 29 and 31 °C for 24 h induces better survival and decreases the extent of brain damage in rats subjected to asphyxial cardiac arrest for 8 min (Jinka et al. 2015; Tupone et al. 2016 ).
Consistent data demonstrate that adenosine acting on adenosine A 1 receptor reduces the ischemia-evoked increase of excitatory transmission. In brain slices, the OGD-induced depression of synaptic transmission is reversed by administration of selective adenosine A 1 receptor antagonists (Pedata et al. 1993 ) that also increase OGD-evoked aspartate and glutamate efflux (Marcoli et al. 2003) , impair the recovery of synaptic potentials (Sebastião et al. 2001) , and shorten the onset of anoxic depolarization (AD) induced by hypoxia (Lee and Lowenkopf 1993) . Depression of excitatory synaptic transmission brought about by adenosine A 1 receptors during hypoxia/ischemia involves AMPA receptor downregulation (Stockwell et al. 2016) in particular the internalization of GluA1 and GluA2 subunit-containing AMPA receptors (Stockwell et al. 2016) . Depression of excitatory synaptic activity and a cross talk with A 2A receptor are crucial for the functional recovery of hippocampal circuits upon reoxygenation when adenosine A 2A receptors play a critical role by increasing excitatory amino acid efflux (Stockwell et al. 2017 ). The A 1 -mediated depression of excitatory synaptic transmission may also be due to the enhancement of inhibitory synaptic transmission in CA1 neurons (Liang et al. 2009) .
In in vitro studies, both adenosine and selective A 1 receptor agonists reduce neuronal damage following hypoxia and/or OGD in primary cortical or hippocampal cell cultures (Daval and Nicolas 1994) and brain slices (Mori et al. 1992) . A 1 receptor agonists increase survival in anoxia and anoxia/reoxygenation and decrease reactive oxygen species (ROS) production, while A 1 receptor blockade increases ROS release and cell death in primary neuronal cultures (Milton et al. 2007) . Studies in support of the neuroprotective role of adenosine A 1 receptor stimulation demonstrate that hippocampal slices from A 1 receptor knockout (KO) mice showed a markedly reduced and delayed protective response to hypoxia compared to slices from wild-type (WT) mice (Johansson et al. 2001 ). In astrocytes prepared from A 1 receptor KO mice, more pronounced hypoxic cytotoxicity was observed (Bjorklund et al. 2008) . In murine astrocytes exposed to hypoxic injury, adenosine, through activation of A 1 and A 3 receptors, inhibits accumulation of the lipopolysaccharide (LPS)-induced hypoxia-inducible factor-1 (HIF-1), a master regulator of oxygen homeostasis (Gessi et al. 2013) .
In in vivo animal models of global cerebral ischemia, it has been demonstrated that local administration of an adenosine analogue, 2-chloroadenosine (CADO), and of a nonselective A 1 receptor agonist, N6-(L-2-phenylisopropyl) adenosine (L-PIA), attenuates neuronal loss in the CA1 region of the rat hippocampus (Domenici et al. 1996; Evans et al. 1987 ). The acute systemic or intracerebroventricular (i.c.v.) injection of the A 1 agonists cyclohexyladenosine (CHA) and R-phenylisopropyl-adenosine (R-PIA) improves neurological deficits (Heron et al. 1994; Von Lubitz and Marangos 1990; Zhou et al. 1994) , protects the CA1 region of the hippocampus (Von Lubitz et al. 1988) , and prevents the reduction of adenosine A 1 receptors (Daval et al. 1989) in rats or gerbils. Similarly, acute administration of the A 1 agonists N6-cyclopentyladenosine (CPA) and 2-chloro-N(6)-cyclopentyladenosine (CCPA) reduces mortality and the loss of neurons after global forebrain ischemia in the gerbil (Von Lubitz et al. 1994a ). Systemic administration of the A 1 receptor agonist adenosine amine congener (ADAC) after global ischemia in the gerbil increased survival, preserved neuronal morphology, and maintained spatial memory and learning ability (Phillis and Goshgarian 2001; von Lubitz et al. 1996) .
Several intracellular mechanisms might account for adenosine A 1 receptormediated neuroprotection in hypoxia/ischemia. Postischemic intraperitoneal (i.p.) administration of adenosine amine congener (ADAC) resulted in preservation of microtubule-associated protein 2 (MAP-2) . CCPA administered i.c.v. before focal ischemia reduces lipid peroxidation in the cerebral cortex (Sufianova et al. 2014) . Chronic coadministration of CCPA and vitamin C i.p. after global ischemia, induced by common carotid arteries ligation, minimized ischemiareperfusion damage by increasing the expression of antiapoptotic protein Bcl-2 and decreasing the expression of proapoptotic protein Bax in mice (Zamani et al. 2013) .
In accordance with a protective role of adenosine A 1 receptors in ischemia, acute administration of adenosine A 1 antagonists exacerbates the damage (Phillis 1995) . However, chronic administration of adenosine receptor antagonists administered before an ischemic insult reduced the neuronal injury (Rudolphi et al. 1989) , and chronic administration of A 1 agonists worsened survival and increased neuronal loss (Jacobson et al. 1996) . It has been suggested these phenomena depend on A 1 receptor upregulation and desensitization, respectively.
Plastic changes in A 1 receptors are critical to understand the effects of adenosine A 1 agonists/antagonists but also whether adenosine maintains its neuroprotective efficiency after ischemia. Several studies have shown that short periods of focal or global ischemia produced a long-lasting decrease in the density of A 1 receptors (Lee et al. 1986 ). In rat hippocampal slices, hypoxia leads to a rapid (<90 min) desensitization of A 1 receptor that is likely due to an internalization of A 1 receptors in nerve terminals (Coelho et al. 2006 ), a process that may result in hyperexcitability and increased brain damage. In a chronic cerebral ischemic mouse model induced by common carotid artery occlusion, A 1 receptor downregulation, a decreased proteolipid protein (a marker of white matter myelination), inhibition of the antiinflammatory interleukin-10 (IL-10) production, and cognitive impairment measured by the Morris water maze test have been reported (Cheng et al. 2015) . However it has been reported that A 1 receptor KO mice, when exposed to global ischemia, do not show increased neuronal damage in the CA1 region of the hippocampus, in the cortex, or in the striatum (Olsson et al. 2004 ). These discrepancies may reflect development of compensatory mechanisms after genetic deletion.
In models of hypoxia-ischemia in neonatal rats, it was reported that A 1 receptors contribute to protection of hypoxic brain (Bona et al. 1997) . In agreement, most recently it has been reported that A 1 receptor KO neonatal mice, from 10 to 17 days after brain hypoxia/ischemia, displayed larger infarctions, cognitive impairment, and exaggerated activation of myeloid cells (Winerdal et al. 2016) . Since inflammation greatly affects the outcome after neonatal brain injury, activation of myeloid cells is proposed as cause of the increased damage in A 1 receptor KO neonatal mice, (Winerdal et al. 2016) . Thus, the decrease of adenosine A 1 receptors (Aden et al. 1994 ) and increase of adenosine deaminase (Pimentel et al. 2015 ) that has been described after rat neonatal hypoxia/ischemia would worsen hypoxic brain damage in neonatal period. On the other end, adenosine acting on A 1 receptors appears to mediate hypoxia-induced brain ventriculomegaly during early postnatal development (Turner et al. 2003) . It should be remembered that in the formation of the central nervous system (CNS), A 1 receptor activation potently inhibits the development of axons and can lead to leukomalacia (Rivkees et al. 2001) . Notably, caffeine, a competitive antagonist of adenosine A 1 , A 2A , and A 2B receptors, that is commonly used in neonates against apnea of prematurity has become a candidate for neuroprotection (Schmidt et al. 2007) .
Adenosine by stimulating A 1 receptors plays a crucial role in the "precondition phenomenon" consisting in protection by sublethal anoxic/ischemic insults from subsequent ischemic insults. The A 1 receptor agonist, CADO, markedly enhanced and A 1 receptor antagonists completely prevented the protective effect of ischemic preconditioning in rat hippocampal slices (Pugliese et al. 2003) . In accordance with in vivo models of ischemia, the selective A 1 antagonist, 8-cyclopentyl-1,3-dipropylxanthine (DPCPX), attenuated the neuroprotective effect of ischemic preconditioning (Cui et al. 2013 ) and CCPA pretreatment-induced ischemic tolerance against cerebral ischemia/reperfusion injury induced by middle cerebral artery occlusion (MCAo) in the rat (Hu et al. 2012) . Preconditioning induced also by limb remote ischemia contributes neuroprotective effects against rat focal cerebral ischemic injury induced by transient MCAo, and the selective A 1 antagonist DPCPX abolished the protective effects demonstrating the involvement of A 1 receptors (Hu et al. 2012) . Interestingly ischemic preconditioning-induced neuroprotection appears transferable among cells through intervention of A 1 receptors as studied in human neuroblastoma SH-SY5Y cells (Yun et al. 2014) . Peculiarly, adenosine A 1 receptors activation is involved in the ischemic tolerance in mice induced by a ketogenic diet (a high-fat, low-carbohydrate diet that increases acetyl-CoA that is involved in ketone body formation that represents an alternative energy source for brain cells under conditions of glucose deprivation) (Yang et al. 2017) .
Although data, on the all, demonstrate a neuroprotective effect of adenosine through A 1 receptors during ischemia, the use of selective A 1 agonists is hampered by undesirable peripheral effects such as sedation, bradycardia, and hypotension. Interestingly, nowadays it is proposed that partial agonists at A 1 receptor may be devoid of hemodynamic effects being therefore valuable drugs in ischemia (Baltos et al. 2016) . The possibility that new adenosine A 1 receptor partial agonists are protective in ex vivo and in vitro experimental models of ischemia was recently discussed by Martire and coworkers (personal communication 2016) .
Adenosine A 2A Receptors in Brain Ischemia

Brain A 2A Receptors Increase Glutamatergic Excitatory Transmission
A 2A receptors play an important modulation of synaptic transmission counteracting depression brought about by A 1 receptor (Lopes et al. 2011 ). In the CA1 area of the rat hippocampus, the selective A 2A receptor agonist, 2-p-(2-carboxyethyl) phenethylamino-5′-Nethylcarboxamidoadenosine hydrochloride (CGS21680), clearly reduces the OGD-induced depression of synaptic activity (Latini et al. 1999) .
, delay the appearance of AD, a phenomenon strictly related to cell damage and death (Somjen 2001) , protect from the synaptic activity depression brought about by a severe (7 min) OGD period, and protect CA1 neuron and astrocyte from injury (Pugliese et al. 2009 ). The same effects of ZM241385 were observed after a severe 9 min OGD period in the gyrus dentatus of the hippocampus . Protective effects against OGD by A 2A receptor antagonists are greatly attributed to antagonism of excessive excitatory transmission. In fact adenosine A 2A receptor regulates glutamatergic excitatory transmission by several mechanisms. Adenosine by stimulating A 2A receptors located presynaptically on glutamatergic terminals can directly regulate glutamate outflow under normoxic (Lopes et al. 2002) and ischemic conditions (Marcoli et al. 2003) . Moreover A 2A receptors modulate glutamate uptake transporter. In particular, A 2A receptors located on astrocytes mediate inhibition of glutamate uptake by glutamate transporter-1 (GLT-1) (Pinto-Duarte et al. 2005 ). An imbalance of A 1 /A 2A receptor expression might also contribute to inhibition of excitatory synaptic transmission under ischemia. Short periods of global ischemia decrease A 1 adenosine receptor density in the brain likely due to an internalization of A 1 adenosine receptors in nerve terminals (Coelho et al. 2006) , thus switching the balance toward A 2A receptor-mediated effects. Moreover, adenosine acting on A 2A receptor increases AMPA (Dias et al. 2012 ) and NMDA receptor function (Rebola et al. 2008 ).
All the above-described modulatory effects of the glutamatergic excitatory transmission by adenosine A 2A receptors might be relevant in in vivo ischemia. A definite overexpression of A 2A receptors was found in vivo in neurons of the striatum and cortex 24 h after focal ischemia (Trincavelli et al. 2008) . The A 2A agonist CGS21680 increases excitatory amino acid outflow from the ischemic cortex during in vivo ischemia (O'Regan et al. 1992) .
Several studies demonstrated that antagonists of adenosine A 2A receptors were protective in in vivo models of global ischemia. Gao and Phillis (1994) [4,3a] quinoxalines (CP66713), both administered preischemia and protected against hippocampal cell injury during global forebrain ischemia in gerbils (Phillis 1995; von Lubitz et al. 1995) . The selective A 2A receptor antagonist, ZM241385, administered preischemia, reduced hippocampal injury, and improved performance in the Morris water maze in hyperglycemic four-vessel occluded rats (Higashi et al. 2002) . In all these studies, adenosine A 2A receptor antagonists were administered preischemia. However, postischemic administration is more relevant to a possible clinical use of drugs in stroke. The selective A 2A receptor antagonist, SCH58261, acutely administered after hypoxia/ischemia in neonatal rats reduced brain damage (Bona et al. 1997) and acutely administered i.p. 5 min after focal ischemia in adult rats was protective from brain damage 24 h thereafter (Melani et al. 2003) . The same antagonist, administered subchronically (i.p., 5 min, 6 and 15 h) after focal ischemia, was protective not only against brain damage but also from neurological deficit (Melani et al. 2006 (Melani et al. , 2009 Pedata et al. 2005 ) and disorganization of myelin (Melani et al. 2009 ) 24 h after focal cerebral ischemia in the adult rat. In the model of global ischemia (i.e., 7 min asphyxic cardiac arrest) in newborn piglets, posttreatment infusion with SCH58261 improved neurologic recovery and protected striatopallidal neurons 4 days after ischemia (Yang et al. 2013 ).
The ability of adenosine A 2A receptor antagonists in protecting against ischemic damage in vivo is largely attributed to the control of excessive glutamatergic transmission and of the ensuing acute excitotoxicity after ischemia. The low dose of SCH58261 that 24 h after ischemia has protected against tissue damage induced by MCAo (Melani et al. 2003) or quinolinic acid (QA) excitotoxicity (Popoli et al. 2002) , has also reduced, in the first 4 h after ischemia, the increase of extracellular glutamate estimated by microdialysis in the striatum (Melani et al. 2003) and has reduced glutamate content in the hippocampus after occlusion of both carotids in the rat (Svenningsson et al. 1997 ). In agreement, adenosine A 2A receptor KO mice are protected from an excess of striatal glutamate outflow and damage induced by transient MCAo ).
In addition, ZM241385, injected directly to intrahippocampus, is protective against excitotoxicity induced by kainate (Jones et al. 1998) , and SCH58261 administered directly in the hippocampus (Mohamed et al. 2016) ameliorates infarct size, memory impairment, and motor incoordination 24 h after occlusion of both carotids in the rat. A further mechanism by which A 2A receptor antagonism is protective may be due to the capability of increasing brain GABA extracellular concentration during ischemia (Cristóvão-Ferreira et al. 2009 ).
SCH58261 behaves as a significant protective agent at a dose (0.01 mg/kg) that does not have cardiovascular effects. This low dose does not affect motor activity in naive animals but decreases controlateral turning behavior after MCAo induced by the monofilament technique (Melani et al. 2003 (Melani et al. , 2006 . At a higher dose, in the range that is effective in different models of Parkinson's disease (PD), the same drug significantly increases motility and rearing in the rat (Svenningsson et al. 1997) .
Control of several intracellular pathways activated by ischemia might account for protection by A 2A receptor antagonism. Twenty-four hours after focal ischemia, the A 2A receptor antagonist SCH58261 has decreased the ischemia-induced activation of p38 mitogen-activated protein kinase (MAPK) in activated microglia (Melani et al. 2006 ) and of JNK MAPK that is mainly expressed in mature oligodendrocytes and in oligodendrocyte progenitors (OPCs) (Melani et al. 2009 ). p38 is considered a death factor in ischemia (Barone et al. 2001) , and phospho-JNK is a factor involved in oligodendrocyte death (Jurewicz et al. 2006) . JNK MAPK KO mice are in fact protected from damage following cerebral ischemia (Kuan et al. 2003) . Reduced activation of JNK might be directly due to A 2A receptors located on OPCs (Coppi et al. 2015) . In fact in primary OPC culture, selective stimulation of A 2A receptors by CGS21680 inhibits maturation of OPCs (Coppi et al. 2013 ) and inhibits " delayed rectifier" K + currents (K DR ) (Coppi et al. 2013 ) that are known to promote proliferation and differentiation of OPC to mature oligodendrocytes, thus preventing myelin deposition.
Direct intrahippocampus administration of SCH58261 after global ischemia, 24 h thereafter, has reduced also phospho-ERK 1/2 bringing to the reduction of different inflammation products and to the increase of the anti-inflammatory cytokine IL-10 ( Mohamed et al. 2016) .
The reduced MAPK activation by SCH58261 might be due to a direct effect of the A 2A receptor antagonists on A 2A receptors located on oligodendrocytes or microglia but also to the overall reduction of the excitotoxic cascade that in the initial hours after in vivo ischemia primes microglial activation and MAPK activation. In fact, oligodendroglial cells are extremely sensitive to glutamate receptor overactivation, and ensuing oxidative stress and p38 and ERK1/2 MAPK activation is definitely induced by glutamate receptor stimulation (Kurino et al. 1995) .
The recent observation that the A 2A receptor antagonist SCH58261 chronically administered after ischemia has not maintained protection 7 days after transient focal ischemia (Melani et al. 2015) supports the idea that the early protection offered by A 2A antagonism is overwhelmed on time by the secondary damage due to blood cell infiltration and neuroinflammation.
Adenosine A 2A Receptor Agonists Are Protective against Ischemic Damage
Considering that A 2A receptor antagonists are protective after ischemia, in an apparent paradoxical manner, also adenosine A 2A agonists were found protective under hypoxia/ischemia. An early study demonstrated that the adenosine A 2A receptor agonist 2-[(2-aminoethylamino)-carbonylethylphenylethylamino]-5'-Nethylcarboxoamidoadenosine (APEC), administered systemically and chronically for 13 days, before a global 10-min ischemia in the adult gerbil, ameliorated animal and neuron survival (von Lubitz et al. 1995) . Also the selective A 2A receptor agonist, CGS21680, administered immediately after 5 min of global ischemia in gerbil at the high dose of 10 mg/kg i.p., exhibited highly significant protection against neuronal loss (Sheardown and Knutsen 1996) . In agreement, A 2A receptor KO mice subjected to chronic cerebral hypoperfusion by permanent stenosis of bilateral common carotid artery showed impairment in working memory, increased demyelination and proliferation of glia, and increased levels of pro-inflammatory cytokines ). The same transgenic mice, at neonatal age, showed aggravated hypoxic/ ischemic injury in comparison to WT littermates (Adén et al. 2003) . Most recently, Melani et al. (2014) have demonstrated that the A 2A receptor agonist, CGS21680, administered at the low dose of 0.01 mg/kg, twice/day for 7 days i.p. (chronic protocol) starting from 4 h after transient (1 h) MCAo, induced protection from neurological deficit, weight loss, cortical infarct volume, myelin disorganization, and glial activation evaluated 7 days after ischemia.
In considering translation to clinic, a main problem of A 2A receptor agonists consists in their cardiovascular effect because adenosine A 2A receptors located on vascular smooth muscle and endothelial cells exert a vasodilatory effect. Relevantly, Melani et al. (2014) have demonstrated that the protective dose (0.01 mg/kg) of CGS21680 does not modify either mean blood pressure or heart frequency. Moreover, adenosine by stimulating A 2A R G s -coupled adenylate cyclase in platelets enhances the intracellular cAMP levels, a potent molecule that inhibits platelet activation (Cooper et al. 1995) having thus potential antithrombotic activity. Therapies under study in ischemia (i.e., neuroprotective drugs including hypothermia or antioxidant/anti-inflammatory strategies) need to be associated with thrombolytic drugs since restoration of oxygen and glucose, at the moment, is considered the best therapy to protect against cell death from stroke (Liu et al. 2017) , although its efficacy may be limited by the potential hemorrhagic effects. Considering that tPA and/or antiplatelet drugs are also routinely used in prevention of the secondary stroke, administration of a further drug that has antiplatelet activity could potentiate a previous antiplatelet therapy increasing the hemorrhagic potential or on the contrary could be useful in maintaining an antiplatelet effect after the primary stroke. However we found (personal unpublished results) that a chronic treatment with CGS21680, twice/day for 7 days at the dose of 0.01 mg/kg administered i.p. in control rats, does not modify platelet aggregation induced by 10 μM ADP (technique described by Ma et al. 2016; Yang et al. 2015 ) (50.9% ± 11.5 of ADP induced aggregation in control n = 3 versus 49.4% ± 1.3 in treated rats n = 4). In agreement, concentrations of CGS21680 that decrease production of free radicals of the oxygen from isolated human neutrophils were calculated three times lower (EC50 300 nM) than those that decrease human platelet aggregation (IC50 1090 nM) (Gessi et al. 2000) . Data suggest that adenosine A 2A receptors exert antioxidant effects and inhibit granulocyte infiltration at doses /concentrations lower than those necessary to inhibit platelet aggregation.
Protection by CGS21680 after ischemia could be attributable to central effects because it easily crosses the BBB. As a vasodilator agent, adenosine acting on A 2A receptors is in fact implicated in cerebral blood flow regulation and might favor brain reperfusion after ischemia. Recently, importance of adenosine receptors located on vasculature as therapeutic targets in cardiovascular pathologies including stroke was pointed out (Sousa and Diniz 2017) . Moreover CGS21680 administered directly into the rat striatum immediately prior to the induction of intracerebral hemorrhage reduces parenchymal neutrophil infiltration and tissue damage: an effect that was related to the inhibition of tumor necrosis factor-α (TNF-α) expression (Mayne et al. 2001) . Activation of central A 2A receptors is known to increase expression and release of neurotrophic factors such as nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF), and glial cell line-derived neurotrophic factor (GDNF) (Sebastião and Ribeiro 2009 ). The increase in neurotrophic factor expression by adenosine A 2A receptor stimulation may contribute to restore neurological functions and cerebral damage after brain ischemia.
A bulk of evidences however indicates that A 2A receptors located on blood cells greatly account for protective effects of adenosine A 2A agonists after ischemia. The adenosine A 2A receptors are expressed in fact both on cells of innate (microglia, macrophages, mast cells, monocytes, dendritic cells, neutrophils) and on adaptive (lymphocytes) immunity. After ischemia altered permeability of BBB allows infiltration of leukocytes (neutrophils, lymphocytes and monocytes) that on their turn exacerbate ischemic damage (Haskó et al. 2008 ). In the transient MCAo model in the rat, selective immunostaining for granulocytes, by anti-HIS-48 antibody, shows numerous infiltrated cells in ischemic striatal and cortical core, 2 days after transient MCAo (Melani et al. 2014) . This is in agreement with observation that after transient MCAo, a peak of neutrophil infiltration occurs at 6 and 48 h thereafter (Zhang et al. 1994) . Seven days thereafter, infiltrated blood cells were anymore observed (Melani et al. 2014 ). Chronic treatment with the A 2A adenosine receptor agonist, CGS21680, 2 days after transient MCAo, has definitely reduced the number of infiltrated blood cells in the ischemic areas (Melani et al. 2014) . The importance of a protracted treatment with the A 2A agonist in order to achieve protection is proved by the observation that the A 2A agonist administered subchronically (4 and 20 h after induction of MCAo) did not prove protective 24 h after permanent MCAo nor 7 days after transient MCAo (Pedata et al. 2014) .
Many studies have reported that selective activation of A 2A receptors directly on blood cells, including platelets, monocytes, some mast cells, neutrophils, and T cells, inhibits pro-inflammatory responses, reduces production of adhesion cell factors, and reduces neutrophil activation, thereby exerting antioxidant and antiinflammatory effects. A 2A receptor activation is known to reduce ischemia-induced rolling, adhesion, and transmigration of various peripheral inflammatory cells (such as lymphocytes, neutrophils) (Haskó et al. 2008) . It has been reported that adenosine A 2A receptors are sensors of inflammatory disease and increase in number in blood cells in different human peripheral and central inflammation-based pathologies including rheumatoid arthritis multiple sclerosis and amyotrophic lateral sclerosis (Borea et al. 2016) . Our (unpublished) results demonstrate that density of adenosine A 2A receptor assayed by RT-PCR in leukocytes isolated from shamoperated (mean ± ES; sham-operated, 1.02 ± 0.02) is not modified 48 h after tMCAo (0.95 ± 0.01) but was significantly decreased after 7 days (0.92 ± 0.03*, unpaired student's t-test, *p < 0.03 vs sham-operated rats; results are expressed as fold increase according to the 2^(−ΔΔCt) method, utilizing as target genes ADORA2A) when infiltrated blood cells were anymore observed (Adén et al. 2003) .
In support that A 2A receptors on blood cells are greatly responsible of the protective effects of A 2A agonists, protection of motor deficits by A 2A receptor agonists systemically administered after spinal trauma is lost in mice lacking A 2A receptors on bone marrow-derived cells (BMDCs) but is restored in A 2A receptor KO mice reconstituted with A 2A receptors on BMDCs (Li et al. 2006) . Moreover, in the spinal cord trauma model in the mouse, CGS21680 protected from damage when injected systemically but not when centrally injected into the injured spinal cord (Paterniti et al. 2011) . Consistent with its anti-inflammatory and immunosuppressive role, the protective effect of adenosine A 2A receptor stimulation has been observed in different pathologies where inflammatory process has an important role in tissue damage such as ischemia/reperfusion liver injury (Day et al. 2004) , spinal cord trauma (Day et al. 2004; Genovese et al. 2010; Paterniti et al. 2011) , rheumatoid arthritis (Mazzon et al. 2011) , acute lung inflammation , intestine ischemia/ reperfusion injury (Di Paola et al. 2010; Odashima et al. 2005) , and experimental autoimmune encephalomyelitis (Xu et al. 2013 ).
A 2A Receptor as Target of Protective Drugs after Ischemia
In conclusion information up to now indicates that stimulation or antagonism of A 2A receptors might be a protective strategy secondary to the time-related development of phenomena typical of trauma and ischemia. Protective effects of A 2A antagonists, at doses that do not modify hemodynamic parameters and inside a therapeutic window compatible with arrival in a stroke unit, would provide protection by dampening central excitotoxicity, while A 2A agonists, at doses that do not modify hemodynamic parameters or platelet activity, provide protection by controlling massive infiltration in the hours after ischemia. Since a major mechanism underlying reperfusion injury is that of poststroke inflammation, targeting anti-inflammatory targets as a combined therapy with pharmacological thrombolysis or mechanical thrombectomy after reperfusion is a potential useful strategy after stroke (Mizuma and Yenari 2017) .
Adenosine A 2B Receptors in Brain Ischemia
Among adenosine receptors, the adenosine A 2B receptor subtype is the least studied and still remains the most enigmatic adenosine receptor subtype because of the relatively low potency of adenosine at this receptor (EC50 value of 24 μM) (Fredholm et al. 2011 ) and the very few specific agonists that have been described so far. Adenosine A 2B receptors, although scarcely, are uniformly expressed throughout the CNS (Dixon et al. 1996) including the hippocampus (Perez-Buira et al. 2007 ). Their expression in neurons, glial, and vascular endothelial cells increases after ischemia and mRNA protein expression of A 2B receptor increased to a greater extent after ischemia-reperfusion than did expression of the other three adenosine receptors (A 1 , A 2A , and A 3 ) 24 h after transient MCAo in the rat (Li et al. 2017) . Thus, during conditions of hypoxia or ischemia when the extracellular adenosine levels rise, A 2B receptors might be well activated (Xu et al. 2013) .
Due to the existence of selective antagonists of A 2B receptors, their role under OGD was most recently investigated. Our recent data demonstrate that, in the CA1 area of the rat hippocampus, the selective A 2B receptor antagonists, N-(4-cyanophenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl) phenoxy]-acetamide (MRS1754) and 8-[4-[4-(4-Chlorophenzyl) piperazide-1-sulfonyl) phenyl]] -1-propylxanthine) (PSB603), prevent the appearance of AD, a phenomenon strictly related to cell damage and death (Pugliese et al. 2006) , and protect from the synaptic activity depression, bringing to a significant recovery of an otherwise disrupted neurotransmission induced by 7-min OGD (see Fig. 14.3) . The damage to CA1 pyramidal neurons, assessed by the decrease of immunofluorescence density of CA1 NeuN + neurons, was completely antagonized by treatment with PSB603 (see Fig. 14.3) (Gaviano et al. 2017) . A 2B receptors are present in mouse hippocampal glutamatergic terminals, where their selective stimulation counteracts the A 1 receptor-mediated inhibition of synaptic transmission (Goncalves et al. 2015) . Moreover, in transfected cells, a synergy with A 2A receptors has been envisaged because adenosine A 2A receptor, when stimulated, facilitates A 2B receptor externalization from the endoplasmic reticulum to the plasma membrane, possibly increasing the formation of the A 2A -A 2B dimer which could regulate glutamate outflow (Moriyama and Sitkovsky 2010) .
In primary murine astrocytes, the expression of A 2B receptor is strongly stimulated by LPS in concert with hypoxia (Gessi et al. 2013) . In human astroglial cells, a selective A 2B antagonist, N-(4-acetylphenyl)-2-[4-(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl) phenoxy]acetamide (MRS1706), completely prevents elongation of astrocytic processes (a morphological hallmark of in vivo reactive astrogliosis) induced by selective stimulation of A 2B receptors (Trincavelli et al. 2004) . The selective A 2B receptor antagonist, MRS1754, administered i.c.v., reduced an early ceramide production from primary astrocytes isolated from the hippocampus of rats subjected to global cerebral ischemia (Gu et al. 2013) . Specific secretion of ceramide from astrocytes has been associated with neuroinflammation and is considered a contributing factor to neuronal dysfunction and damage (Wang et al. 2012) . Such effect of the A 2B antagonist might be due to an early reduction of p38 MAPK activation (Wei et al. 2013) or to reduced expression of the "regulators of G-protein signaling" (RGS) in particular RGS-3 as demonstrated in astrocytoma cells (Eusemann et al. 2015) . A 2B receptor desensitization described on astroglia might represent a cell defense mechanism in ischemia (Trincavelli et al. 2008) . Since A 2B receptors are activated only by high adenosine concentrations as can be reached under brain ischemia, they might represent a good selective therapeutic target for antagonists that, by reducing excitotoxicity and neuroinflammation, can subserve a protective mechanism early after ischemia (Popoli and Pepponi 2012) . Besides brain cells, A 2B receptors are present on blood immune cells, i.e., neutrophils and lymphocytes Gessi et al. 2005) , where in most cases they are coexpressed with A 2A receptors. They are also expressed at low levels on platelets, where they are upregulated following injury and systemic inflammation in vivo and induce inhibition of platelet aggregation (Yang et al. 2010 ). Attenuation of hypoxia-associated increases in tissue neutrophil number in different tissues including brain largely depends on hematopoietic cell A 2B signaling . , a slice where a 7-min OGD was performed (OGD), and a slice where a 7-min OGD was performed in the presence of 50 nM PSB-603 (OGD + PSB), all collected 3 h after the insult. Scale bar, 75 μm. Lower panel: quantitative analyses of NeuN + immunofluorescence in the four experimental groups. Each column represents the area, expressed in pixels (x 10 6 ) above a threshold, maintained constant for all slices investigated. Statistical analysis: One-way ANOVA, Newman-Keuls multiple comparison test: *P < 0.05, OGD vs CTR; # P < 0.05, OGD + PSB vs OGD. CTR, n = 6; OGD, n = 5; OGD + PSB, n = 3. All data in the graphs are expressed as mean ± S.E.M Moreover, A 2B receptors are expressed on the surface of endothelial cells (Feoktistov et al. 2004) where they are upregulated by the hypoxia-inducible factor (HIF-1α) (Eltzschig et al. 2004) . Studies in mice deleted of A 2B receptors on bone marrow cells indicate an important contribution of vascular A 2B receptors in attenuating vascular leakage during hypoxia . The A 2B receptor antagonist MRS1754 increases adhesion in human microvascular endothelial cells (HMEC-1 s) exposed to hypoxia (Eltzschig et al. 2004) , and adenosine A 2B receptor KO mice show increased basal levels of TNF-α and expression of adhesion molecules in lymphoid cells, resulting in increased leukocyte rolling and adhesion (Yang et al. 2006) . Evidences indicate that A 2B receptors are a valuable target to protect heart (Eltzschig et al. 2013 ) and kidney from ischemia . Recent introduction of new pharmacological tools (Hinz et al. 2014) led to understand a role of A 2B receptors in ischemia. The selective A 2B receptor agonist BAY60-658380 systemically administered in mice before in vivo normobaric hypoxia exposure decreases vascular leak in the lung, liver, and colon . It has also been demonstrated (Li et al. 2017 ) that treatment with BAY60-6583 (1 mg/kg intravenously), at the start of reperfusion after brain ischemia induced by 2-h transient MCAO, 24-h thereafter, reduced lesion volume and attenuated brain swelling and BBB disruption. In the presence of tPA (administered after ischemic stroke to dissolve intravascular clots), BAY60-6583 also mitigated sensorimotor deficits and reduced tPA-induced hemorrhages at 24 h (Li et al. 2017 ). The neurovascular protection afforded by BAY60-6583 appears to derive from stimulation of the tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) production, inhibition of tPAinduced matrix metalloprotease (MMP) activation, and prevention of tight junction protein degradation. In fact overactivation of MMP leads to increased cerebrovascular permeability after ischemia-reperfusion injury (Mishiro et al. 2012) . It is proposed that A 2B receptor agonists might be adjuvant to tPA and could be a promising strategy for decreasing the risk of hemorrhages during treatment for ischemic stroke (Li et al. 2017) .
All together these studies point toward a role of central A 2B receptors, in synergy with A 2A receptors in promoting brain excitotoxicity, while A 2B receptors located on vascular endothelial cells would play a pivotal role in attenuating hypoxia-induced increases in vascular leak. A 2B receptor has been described as implicated in dampening vascular adhesion signals and hypoxia-induced inflammation (Koeppen et al. 2011) .
A further possible role of A 2B receptors in hypoxia/ischemia might be secondary to promotion of an angiogenic response because activation of A 2B receptors by adenosine increases endothelial cell proliferation, chemotaxis, capillary tube formation, and release of vascular endothelial growth factor (VEGF) (Feoktistov et al. 2004 ).
Adenosine A 3 Receptors in Brain Ischemia
Adenosine A 3 receptor has an affinity of 300 nM in huis widespread in the rat and mouse brain but compared to A 1 and A 2A receptors has less affinity for adenosine (10-30 nM versus 1 μM) and is detected at relatively low levels (Gessi et al. 2008 ). However, since extracellular adenosine concentrations in the first hours after ischemia reach a μM range (Latini and Pedata 2001; Melani et al. 1999) , also adenosine A 3 receptor is involved in the tonic adenosine effects in ischemia.
Studies currently in the literature concerning the role of adenosine A 3 receptor in the pathophysiology of cerebral ischemia are rather contradictory (Borea et al. 2009; Pedata et al. 2010) . The use of mice with genetic deletion of the A 3 receptors has pointed out a neuroprotective function of adenosine A 3 receptors. Mice lacking A 3 receptors showed in fact increased neurodegeneration in response to repeated episodes of moderate hypoxia (Fedorova et al. 2003) and an increase in cerebral infarction after transient ligation of MCA (Chen et al. 2006 ). Accordingly, a chronic administration (10-day pre-ischemic) of the A 3 agonist N(6)-(3-iodobenzyl)-adenosine-5'-N-methylcarboxamide (IB-MECA) reduced ischemic damage after global forebrain ischemia in the gerbil (von Lubitz et al. 1994b) , and pretreatment with a selective A 3 agonist, 1-[2- methyl]amino]-9H-purin-9-yl]-1-deoxy-N-methyl-ß-Dribofuranuronamide] (Cl-IB-MECA), intracerebroventricularly or repeatedly intravenously administered before MCA ligation decreased the size of infarction-induced by transient MCAo (Chen et al. 2006) .
Under in vitro OGD (5 min), selective activation of adenosine A 3 receptors by a brief (5 min) application of IB-MECA brings about an inhibition of excitatory neurotransmission on cortical neurons (Hentschel et al. 2003) , and application of the selective A 3 receptor antagonist, 3-propyl-6-ethyl-5-[(ethylthio)carbonyl]-2-phenyl-4-propyl-3-pyridine carboxylate (MRS1523), before a brief (2 min) OGD reduces the OGD-induced depression of fEPSP in the CA1 hippocampal area ). These findings indicated an inhibitory role of A 3 receptors on synaptic transmission during brief OGD periods and have suggested that A 3 receptors have a synergistic role with A 1 receptors in decreasing synaptic transmission, thus sustaining the neuroprotective effect of A 1 receptors.
On the other hand, when hippocampal slices are submitted to a severe (7-min) OGD, the selective antagonists of adenosine A 3 receptors abolish or delay the occurrence of AD and significantly protect from the irreversible disruption of neurotransmission caused by the severe ischemic episode in the CA1 region of rat hippocampal slices (Colotta et al. 2007 (Colotta et al. , 2008 (Colotta et al. , 2009 Poli et al. 2017; Pugliese et al. 2006 Pugliese et al. , 2007 . Depression of synaptic transmission following 15-min OGD was prevented by A 3 receptor antagonists also in the CA3 hippocampal area (Dennis et al. 2011) .
To explain results above reported, we should consider that rat cortical neurons exposed to hypoxia in vitro show an increase in activation of protein kinase C (PKC) after selective adenosine A 3 receptor stimulation (Nieber and Hentschel 2006) . If OGD is applied long enough to be considered severe, PKC activation induced by adenosine A 3 receptor could account for an increase in intracellular calcium, which may participate in increasing tissue excitability and thus lead to irreversible synaptic failure. Thus while initially after OGD, massive excitotoxicity may be controlled by adenosine A 3 receptors, later the ensuing cascade of cytotoxic events could be potentiated by prolonged adenosine A 3 receptor stimulation. Moreover ischemiainduced plasticity of A 3 receptors might be relevant to explain the A 3 agonist effects in ischemia. A desensitization of A 3 receptors might account for the effect of a long application (before and during OGD) of Cl-IB-MECA and of new selective A 3 agonists (Volpini et al. 2002 ) that like A 3 antagonists protect from the depression of synaptic activity brought about by prolonged OGD and delay the appearance of AD in the CA1 region of rat hippocampal slices .
A 3 receptor mRNA has been identified in mouse astrocytes, in microglia, and in oligodendrocytes. In human D384 astrocytoma cells, Cl-IB-MECA at relatively low concentration (0.8 μM) reduced ATP depletion and apoptosis caused by hypoxic conditions (Bjorklund et al. 2008) . Primary astrocytes prepared from adenosine A 3 receptor KO mice were more affected by hypoxia than those prepared from WT mice (Bjorklund et al. 2008) . In cultured murine astrocytes, stimulation of A 3 receptors decreases HIF-1 expression induced by LPS under hypoxic conditions (Gessi et al. 2013 ), leading to inhibition of genes involved in inflammation injury (Gessi et al. 2013 ). In the in vivo model of transient MCAo, IB-MECA administered after ischemia proved to decrease the intensity of reactive gliosis involving microglia and astrocytes as evaluated 7 days after ischemia .
Besides being localized on central cells, adenosine A 3 receptors are also localized on blood cells (Gessi et al. 2013) . The state of the art about the role of adenosine A 3 receptors in inflammatory responses appears conflicting because exposure of blood peripheral cell lines to selective adenosine A 3 receptor agonists results in both anti-and pro-inflammatory effects (Borea et al. 2009 ). Choi et al. (2011) have demonstrated that treatment with 2-chloro-N(6)-(3-iodobenzyl)-5'-N-methylcarbamoyl-4′-thioadenosine (LJ529), a selective A 3 agonist administered by intraperitoneal injection 2 and 7 h after transient MCAo, markedly reduced cerebral ischemic injury 24 h thereafter. LJ529 also prevented the infiltration of monocytes and migration of microglia occurring after MCAo. A 3 receptor agonists can mediate their protective effects via anti-inflammatory signaling (inhibition of pro-inflammatory cytokines) and/or concomitant inhibition of innate immune cell trafficking because of A 3 receptor desensitization (Butler et al. 2012) .
As adenosine A 2A receptor, also A 3 receptors are upregulated in lymphocytes obtained from patients affected by chronic autoimmune inflammatory rheumatic diseases, i.e., rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis (Ravani et al. 2017; Varani et al. 2011 ) raising the possibility to exploit adenosine A 2A and A 3 receptors as therapeutic targets to limit the inflammatory responses.
A 3 agonists, under clinical evaluation for the treatment of inflammatory diseases and cancer, demonstrated excellent safety and efficacy (Fishman et al. 2012) .
Overall, results raise the question of the time-related utility of A 3 receptor antagonists/agonists for treatment of ischemia. It may be speculated, that after ischemia, a prolonged treatment with adenosine A 3 receptor agonists protects first by reducing glutamate-mediated excitotoxicity and later on after ischemia, by desensitizing central A 3 receptors and via anti-inflammatory effects mediated by A 3 receptors on blood cells.
Conclusions
Information up to now acquired indicate that adenosine receptors located on any cell type of the brain and on vascular and blood cells partake in either salvage or demise of the tissue after a stroke. They thus represent important targets for drugs having different therapeutic time windows after stroke.
One of the prime adaptive mechanisms in response to hypoxia-ischemia is the cellular activation of adenosine A 1 receptors which inhibits excessive excitatory synaptic transmission. At the same time but, on the contrary, adenosine A 2A and A 2B receptors contribute to excessive excitotoxicity. Unfortunately the use of selective A 1 agonists is hampered by undesirable peripheral effects such as sedation, bradycardia, and hypotension. Early neuroprotective strategies with antagonists of adenosine A 2 receptors would be aimed at targeting the brain parenchima to antagonize excitotoxicity and ensuing production of harmful molecular events responsible for acute brain damage.
In the hours and days after ischemia, adenosine A 2A , A 2B , and A 3 receptors peripherally located on vascular and blood cells may be the targets of drugs aimed at dampening vascular adhesion signals and neuroinflammation.
Overall, a therapeutic strategy with adenosine receptor antagonists/agonists should be carefully evaluated in terms of time after ischemia due to the balance of central versus peripheral adenosine receptor-mediated effects over time after ischemia. Besides early neuroprotective strategies with A 2A and A 2B receptor antagonists, strategies aimed at targeting events in a longer time window of days/weeks after ischemia appear promising in antagonizing inflammation and neurovascular protection and promoting neuroplasticity and neurogenesis. Considering that tPA is routinely used after ischemic stroke to dissolve intravascular clots, most recent data indicate that A 2B receptor agonists, by providing neurovascular protection, might be a promising strategy against BBB damage and permeability and for decreasing the risk of hemorrhages after stroke.
Compounds active at adenosine receptors are drugs under development and already exist in therapy or in clinical experimentation for other indications; some of them could enter in a reasonable time in clinical trials for stroke. Still there is urgent need of novel compounds to be developed with higher selectivity, oral bioavailability, stability in vivo, longer half-life, and better capability to cross the BBB.
